Antimicrobial resistance report
This article was originally published in The Rose Sheet
Executive Summary
Antimicrobial Resistance Interagency Task Force presents second 1annual progress report on a public health action plan to combat antimicrobial resistance during a meeting June 25 in Bethesda, Md. Second annual report focuses on domestic issues, such as implementing a national antimicrobial resistance surveillance plan. Interagency task force includes Centers for Disease Control and Prevention, FDA and National Institutes of Health. Evaluation of benefits and risks in consumer products such as soap were included in action plan unveiled by HHS in 2001 (2"The Rose Sheet" Jan. 22, 2001, In Brief)...
You may also be interested in...
Antimicrobial action plan
Evaluation of benefits/risks of incorporating antimicrobial disinfectants or chemicals into consumer products such as soap included in final interdepartmental antimicrobial resistance action plan unveiled by HHS Jan. 18. Although not specified in the final version, a draft released in June said agencies likely will consider whether such products "have any efficacy in reducing infection" and if they "play a role in promoting drug resistance" (1"The Rose Sheet" June 26, 2000, p. 8). Developed by the Task Force on Antimicrobial Resistance, the plan designates priorities, identifies responsible agencies and creates timelines for facilitating surveillance, prevention and control, research and product development to address antimicrobial resistance. CDC, NIH and FDA are leading task force of 10 agencies and departments
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.